Form 483

Novo Nordisk Production Belgium SA Form 483, 2019-06-19

FDA issued a Form 483 to Novo Nordisk Production Belgium SA on 2019-06-19 with 3 public-safe observations.

483· Form 483 issuedBiologics3 observations

Novo Nordisk Production Belgium SA · Brussels, Belgium · Issued June 19, 2019

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

19 Jun 2019
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Mihaly S Ligmond

19 Jun 2019
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Mihaly S Ligmond

19 Jun 2019
21 CFR 211.194(a)(4)

Complete Test Data

Cited by Mihaly S Ligmond

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(4)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere